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Abstract: Most women with early breast cancer (BC) have an excellent prognosis and will 
remain disease-free for many years after treatment. However, bone-specific side effects of 
cancer therapies can have a negative effect on patients’ long-term bone health. The accelerated 
bone loss associated with BC therapies, especially endocrine therapy, can put women at risk 
for osteoporosis and fractures later in life. Recent treatment guidelines have now begun to 
address the need for bone-preserving measures to be included in adjuvant therapy regimens. 
Bisphosphonates have long been used to treat osteoporosis, as well as bone metastases in patients 
with advanced cancers. Furthermore, in the adjuvant BC setting, the intravenous bisphosphonate 
zoledronic acid has emerged to play an important role. Several large, randomized phase III 
trials involving a total of approximately 4,000 premenopausal and postmenopausal women 
with early BC demonstrated the bone-protective effects of adjuvant zoledronic acid (4 mg every 
6 months). Additionally, these same trials also showed significant improvement in disease-free 
survival for patients receiving adjuvant endocrine therapy plus zoledronic acid that was over 
and above the benefit achieved with endocrine therapy alone. The results of these zoledronic 
acid trials will be reviewed herein, and evidence supporting the antitumor effects of adjuvant 
zoledronic acid will be discussed.
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Introduction
Improvements in screening and public awareness in industrialized nations have resulted 
in the majority of breast cancers being diagnosed at an early stage.1 Because most 
patients with early breast cancer will survive for many years, managing the negative 
side effects of long-term cancer therapies is important for preserving patients’ qual-
ity of life (QOL). For example, known side effects of many breast cancer therapies 
include reduced bone mineral density (BMD) and diminished bone quality and micro-
architecture, both of which contribute to increased risk of fracture in women with 
breast cancer.2,3 Chemotherapy can have a direct negative effect on bone-producing 
cells (osteoblasts), and can also cause ovarian failure and premature menopause in 
premenopausal patients.4,5 For example, a chart review of 130 postmenopausal patients 
who received chemotherapy for breast cancer demonstrated that their age-adjusted 
BMD was at least 0.5 standard deviations below those of the group that did not receive 
chemotherapy (a decrease that may be equated with a 40% increased risk of fracture).4 
In premenopausal patients who developed chemotherapy-induced ovarian failure there 
was significant BMD loss in the spine at both 6 and 12 months compared with patients 
who did not lose ovarian function (p = 0.0001 for both).5OncoTargets and Therapy 2009:2 96
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Because the majority of breast cancers are hormone 
responsive,6 endocrine therapy has become the treatment of 
choice in these patients. However, because endocrine therapy 
reduces estrogen levels, it is also associated with rapid bone 
loss in both pre- and postmenopausal women.7–12 Several clini-
cal trials in postmenopausal women with early breast cancer 
demonstrated significant increases in bone loss and fracture 
incidence in patients receiving both steroidal and nonsteroi-
dal aromatase-inhibitor therapy.7,8,10–12 For example, in the 
Arimidex®, Tamoxifen, Alone or in Combination (ATAC) 
trial (N = 6186), patients receiving anastrozole experienced 
significantly more fractures (11%) compared with patients 
receiving tamoxifen (7.7%; p  0.0001).10 The increased 
fracture rate may be explained by the rapid bone loss observed 
in patients receiving anastrozole in the bone substudy of this 
trial. Within 2 years of beginning therapy, patients receiving 
anastrozole had lost approximately 4% BMD at both the 
lumbar spine and total hip compared with baseline (p  0.001 
for both),8 and after 5 years the anastrozole group had lost 
6.08% and 7.24% BMD at the lumbar spine and hip, respec-
tively (p  0.0001 for both compared with tamoxifen).13 
Similarly, in the Breast International Group (BIG) 1–98 trial 
(N = 8010), postmenopausal women with early breast cancer 
receiving letrozole experienced significantly more fractures 
than patients receiving tamoxifen (5.7% versus 4.0%, respec-
tively; p  0.001).12 In the Intergroup Exemestane Study (IES; 
N = 4724) after 2 to 3 years of tamoxifen therapy, patients 
receiving exemestane lost approximately 3% in lumbar spine 
BMD and fracture incidence was significantly higher com-
pared with those who continued to receive tamoxifen (7.0% 
versus 4.9%; p = 0.003).7,14 Results from these trials and others 
indicate that women with breast cancer receiving endocrine 
therapy are at increased risk for fracture.
Major determinants of a woman’s lifetime fracture 
risk include peak bone mass at maturity and rate of bone 
loss later in life.15 Therefore, not only does natural bone loss 
after menopause contribute to fracture risk, but any cancer 
therapy that prematurely decreases BMD can further increase 
a patient’s fracture risk. As a result, clinical guidelines 
have been developed for managing bone health issues in 
breast cancer patients. Early guidelines to address bone 
health issues in patients with breast cancer, like those used 
to guide treatment for postmenopausal osteoporosis,15,16 
relied on BMD as the primary indicator of treatment (ie, 
T-score  –2.5).17 However, newer recommendations have 
evolved that can be used to assess a patient’s fracture risk 
based on clinical risk factors with or without the addition of 
BMD measurements.18–20
Therapy to prevent treatment-associated bone loss in 
women with breast cancer has evolved alongside improve-
ments in endocrine therapy. Oral bisphosphonates have 
demonstrated some efficacy in this setting. In 1 small trial 
in premenopausal women with chemotherapy-induced 
ovarian failure (N = 73), oral clodronate slowed but did not 
prevent bone loss.21 Two small studies in postmenopausal 
women receiving anastrozole showed that weekly risedro-
nate (N = 234) and monthly ibandronate (n = 50) increased 
BMD at the lumbar spine and hip in patients with osteopenia 
at baseline.22,23 In the adjuvant therapy setting, zoledronic 
acid has demonstrated significant efficacy for prevention of 
treatment-associated bone loss in women with early breast 
cancer. In several large, phase III trials, which included a 
total of 3996 patients, zoledronic acid (4 mg every 6 months) 
improved BMD in pre- and postmenopausal women receiv-
ing adjuvant endocrine therapy for early breast cancer.9,24–26 
In addition to the bone health benefits of zoledronic acid, 
preclinical evidence and recent clinical data have revealed 
that zoledronic acid has significant antitumor activity that 
extends beyond bone (ie, induction of tumor cell apoptosis; 
inhibition of tumor cell adhesion, invasion, and proliferation; 
synergy with chemotherapy; and activation of the immune 
system).27–38 As evidenced by data from preclinical studies, 
zoledronic acid can interfere with many of the steps necessary 
for tumor metastasis, which may explain the clinical benefits 
observed with zoledronic acid in clinical trials (Figure 1).39 
This review will compare current and emerging guidelines 
for managing bone health in breast cancer survivors, examine 
the evidence for using zoledronic acid in preventing cancer 
treatment-induced bone loss (CTIBL), and review the recent 
results that demonstrate the antitumor effects of zoledronic 
acid in the clinical setting.
Assessing guidelines for managing 
bone health in women with breast 
cancer
Historically, clinical guidelines for managing bone health in 
women with breast cancer have relied on BMD measurements 
to guide pharmacologic intervention. For example, the 2003 
American Society of Clinical Oncology (ASCO) guidelines 
recommended bisphosphonate therapy only when BMD 
T-scores fall into the osteoporotic range (T-score  −2.5).17 
However, evidence from a variety of clinical trials has since 
clearly demonstrated that patients have significantly increased 
fracture risk long before becoming osteoporotic. In the National 
Osteoporosis Risk Assessment (NORA) study of healthy 
postmenopausal women between 50 and 104 years of age OncoTargets and Therapy 2009:2 97
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(N = 149,524; mean age 64.5 years), the majority of fractures 
(82%) occurred in women who had normal (T-score  −1.0) 
or osteopenic BMD (T-score between –1.0 and –2.5).40 
This suggests that fracture risk increases long before a 
woman’s BMD reaches the clinical definition of osteoporosis 
(T score  −2.5).
Beyond the influence of BMD on fracture risk, a number 
of clinical risk factors have been shown to contribute to frac-
ture risk independently of BMD in postmenopausal women.41 
In fact, a recent systematic review of published literature 
found that many of the clinical risk factors for fracture (with 
and without BMD) can be used to assess fracture risk and 
guide treatment decisions in women with breast cancer.20 
After critical review of the published literature, the authors 
recommended intervention with bisphosphonate therapy (eg, 
zoledronic acid 4 mg every 6 months) for women with breast 
cancer initiating or receiving aromatase inhibitor therapy who 
have any 2 of the following risk factors: T-score  −1.5, 
age  65 years, low body mass index (BMI;  20 kg/m2), 
family history of hip fracture, personal history of fragility 
fracture after age 50, oral corticosteroid use  6 months, and 
smoking (Figure 2).20 Recently, the Fracture Risk Assessment 
Tool (FRAX®), a Web-based algorithm, was developed 
by the World Health Organization (WHO) to evaluate 
patient fracture risk, and is based on individual patient 
models that integrate the risks associated with clinical risk 
factors and femoral-neck BMD.18 The FRAX computer 
algorithms give the 10-year probability of hip fracture or 
any major osteoporotic fracture (clinical spine, forearm, 
hip, or shoulder). This tool takes into consideration several 
independent risk factors to assess fracture risk and can be 
used with or without BMD evaluations. Because the FRAX 
tool was designed to evaluate fracture risk in healthy women, 
it does not include the risks associated with chemotherapy, 
ovarian suppression/ablation, or endocrine therapy, and 
therefore it will likely underestimate the fracture risk in 
patients with breast cancer. Therefore, overall fracture risk 
assessment may include the FRAX tool, but should also 
include cancer-specific guidelines that take into account the 
contribution of cancer therapies. Overall, these treatment rec-
ommendations and fracture risk evaluation tools emphasize 
the importance of a comprehensive fracture-risk assessment 
and may help to identify women who will benefit from early 
intervention, especially in the early breast cancer setting.
Zoledronic acid for preventing bone 
loss during cancer therapy
It is clear that a patient’s overall fracture risk is a function 
of both BMD and clinical risk factors, and preventing bone 
loss has been shown to reduce long-term fracture risk. In the 
Figure 1 Antitumor effects of zoledronic acid that may contribute to improved disease-free survival in the adjuvant therapy setting.   Adapted by permission from Macmillan 
Publishers Ltd. Mundy Gr, et al. Nat Rev Cancer. 2002;2(8):584–593.39 Copyright © 2002.OncoTargets and Therapy 2009:2 98
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setting of postmenopausal osteoporosis, bisphosphonates 
have long been used to prevent and reverse age-related bone 
loss. The nitrogen-containing bisphosphonate zoledronic 
acid inhibits osteoclast-mediated bone resorption and has 
been approved to treat postmenopausal osteoporosis and 
to prevent skeletal-related events (SREs) associated with 
bone metastases from advanced breast cancer and other 
solid tumors.42,43
More recently, zoledronic acid (4 mg intravenously every 
6 months) demonstrated significant bone-protective effects 
in the Austrian Breast and Colorectal Cancer Study Group 
Trial 12 (ABCSG-12; N = 1803) in premenopausal women 
with early hormone-responsive breast cancer receiving adju-
vant endocrine therapy. The bone substudy of ABCSG-12 
(n = 404) focused on the effect of zoledronic acid on BMD 
during endocrine therapy.44 Patients who received endocrine 
therapy alone (goserelin plus tamoxifen or goserelin plus 
anastrozole) had significant bone loss during 3 years of 
therapy, resulting in an overall 14.4% loss from baseline 
(p  0.0001). In the same study, patients who received 
endocrine therapy plus zoledronic acid maintained stable 
BMD during the 3 years of treatment. Furthermore, after a 
median follow-up of 60 months (2 years after completing 
therapy), patients who had received endocrine therapy alone 
still had BMD below baseline levels (Figure 3).9 In contrast, 
patients who had received endocrine therapy plus zoledronic 
acid during the same period had significantly improved BMD 
compared with baseline, suggesting that zoledronic acid con-
tinues to improve BMD even after treatment completion.
Several other phase III studies of zoledronic acid (4 mg 
intravenously every 6 months) have also demonstrated sig-
nificant bone-protective effects during endocrine therapy for 
early breast cancer. The Zometa®-Femara® Adjuvant Synergy 
Trials (Z-FAST, ZO-FAST, and E-ZO-FAST) compared 
upfront versus delayed zoledronic acid in 2194 postmeno-
pausal women with early breast cancer receiving adjuvant 
letrozole. Patients in the upfront group received zoledronic 
acid concurrently with letrozole, and those in the delayed 
Figure 2 Management recommendations for patients with breast cancer receiving aromatase inhibitor (Ai) therapy, based on results from breast cancer trials in patients 
and healthy controls. aif patients experience annual decrease in bone mineral density (BMD) of 5% (using the same imaging machine), secondary causes of bone loss such 
as vitamin D deficiency should be evaluated and bisphosphonate therapy considered. Use lowest T-score from 3 sites. Adapted from Hadji P, et al. Practical guidance for the 
management of aromatase inhibitor-associated bone loss.  Ann Oncol. 2008;19(8):1407–141620 by permission of Oxford University Press.
Abbreviation: BMi, body mass index.OncoTargets and Therapy 2009:2 99
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group received zoledronic acid only after a postbaseline BMD 
T-score  –2.0 or after experiencing a nontraumatic fracture. 
After a median follow-up of 36 months in the Z-FAST trial 
(N = 602), patients in the upfront zoledronic acid group had 
improved BMD compared with baseline, and those in the 
delayed group had lost BMD, resulting in a significant 6.7% 
difference in lumbar spine BMD between the upfront and 
delayed groups (p  0.0001).45 Similar bone-protective effects 
of upfront versus delayed zoledronic acid were seen after 
36 months in the ZO-FAST trial (9.3% difference in lumbar 
spine BMD, p  0.0001; N = 1065),46 and after 12 months 
in the E-ZO-FAST trial (5.4% difference in lumbar spine 
BMD, p  0.0001; N = 527).26 Although these trials were 
not designed or powered to assess differences in fracture rates 
between groups, there was a trend toward fewer fractures for 
upfront versus delayed zoledronic acid (2.9% versus 3.7%; 
hazard ratio [HR] = 0.78; p = 0.34 for all 3 trials combined).
Chemotherapy-induced premature menopause can increase 
the rate of bone loss, decreasing BMD and increasing a 
patient’s long-term risk of osteoporosis and fracture.5 In 2 pilot 
studies (N = 120; N = 101), zoledronic acid prevented bone 
loss associated with adjuvant chemotherapy in premenopausal 
women.47,48 In contrast with the established zoledronic acid 
dose (4 mg every 6 months) used in the adjuvant endocrine 
therapy setting (eg, ABCSG-12 and Z-FAST), the frequency 
of zoledronic acid dosing has not been standardized in the 
adjuvant chemotherapy setting. In 1 randomized phase II trial, 
120 premenopausal and postmenopausal patients with stage II 
or III breast cancer received chemotherapy (epirubicin and 
docetaxel, both 75 mg/m2) plus concurrent zoledronic acid 
(4 mg every 3 weeks) or placebo for 1 year.47 After 1 year, both 
premenopausal and postmenopausal patients who received 
zoledronic acid had maintained stable BMD at all sites tested. 
During the same period, patients who received chemotherapy 
without zoledronic acid had significant BMD loss at the hip 
(−4.5%; p  0.0001) and nonsignificant BMD loss at the spine 
(−2.7%; p = 0.057). Overall, premenopausal patients had the 
greatest loss of BMD at both sites (–5.9%; p = 0.0004 at the hip, 
and −5.7%; p = 0.0167 at the spine). In another randomized, 
double-blinded, 1-year, phase III trial in 101 premenopausal 
women with early breast cancer receiving adjuvant chemo-
therapy, zoledronic acid (4 mg every 3 months) also prevented 
bone loss.48 After 1 year, the BMD of placebo-treated patients 
had significantly decreased by 4.4% at the lumbar spine 
(p = 0.0001), and by 2.1% at the total hip (p = 0.02) compared 
with baseline (Figure 4).48 During the same period, zoledronic 
acid-treated patients maintained stable BMD compared with 
baseline (Figure 4).48 Taken together, the available evidence 
indicates that zoledronic acid effectively prevents bone loss 
associated with breast cancer therapies in both premenopausal 
and postmenopausal patients.
Emerging evidence for prevention 
of disease recurrence with adjuvant 
zoledronic acid
In addition to its bone-protective effects, zoledronic acid 
has also demonstrated antitumor properties in the adjuvant 
setting. In the main analysis of ABCSG-12 (N = 1803), 
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Figure 3 Zoledronic acid improves bone mineral density (BMD) from baseline to 60 months during adjuvant endocrine therapy.  Patients were randomly assigned to anastrozole 
or tamoxifen ± zoledronic acid (4 mg every 6 months) for 36 months, then no treatment from 36 to 60 months. P values were calculated using 2-sample t-tests for mean 
differences from baseline. reprinted from Lancet Oncol,   vol 9, Gnant M, et al.   Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast 
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Gnant Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
premenopausal patients who received zoledronic acid had 
a 36% relative reduction in the risk of disease progression 
(HR = 0.64; 95% confidence interval [CI] = 0.46, 0.91; 
p = 0.01) compared with endocrine therapy alone (Figure 5).49 
Notably, reductions in disease recurrence were observed at 
all sites (ie, contralateral breast cancer, locoregional recur-
rence, visceral metastases, and bone metastases), and were 
not limited to bone. However, at 47.8 months’ median follow-
up, the addition of zoledronic acid did not significantly 
reduce the risk of death (HR = 0.60; 95% CI = 0.32, 1.11; 
p = 0.11); further follow-up is planned to determine whether 
differences in survival between groups will reach statistical 
significance at later timepoints. In the multivariate analyses, 
which estimate the effects of baseline variables (eg, age, 
tumor stage) on the relative risk of an event, zoledronic 
acid-treated patients had a significant 33% relative reduc-
tion in the risk of disease progression (HR = 0.67; p = 0.02) 
compared with no zoledronic acid. In the same analysis, 
the relative risk of disease progression was significantly 
increased by 1.5- to 2.1-fold for patients with T2 or grade 3 
or 4 tumors or lymph node involvement (p  0.05 for all), 
although high progesterone-receptor expression was associ-
ated with significantly reduced risk of disease progression 
(HR = 0.50; p = 0.001).
Zoledronic acid also appears to have antitumor properties 
in postmenopausal patients receiving adjuvant endocrine 
therapy. In a 12-month integrated analysis of the Z-FAST and 
ZO-FAST trials (N = 1667), disease recurrence was signifi-
cantly less frequent in patients who received upfront zoledronic 
acid compared with the delayed zoledronic acid group (0.84% 
versus 1.9%, respectively; p = 0.0401).24 After longer follow-
up (24 months), results from the integrated analysis demon-
strated a significant 43% improvement in disease-free survival 
(DFS) with upfront zoledronic acid (HR = 0.573; p = 0.0183).50 
Similarly, at 36 months’ median follow-up in the ZO-FAST 
trial (N = 1065), upfront zoledronic acid significantly improved 
DFS by a relative 41% (HR = 0.588; p = 0.0314).46 Taken 
together, the results from trials in both premenopausal and 
postmenopausal patients with early breast cancer indicate that 
adding zoledronic acid (4 mg every 6 months) to adjuvant 
endocrine therapy not only prevents therapy-associated bone 
loss, but can also significantly improve DFS.
Zoledronic acid (4 mg every 6 months) was well tolerated 
in patients receiving adjuvant endocrine therapy, with 
transient infusion-site reaction and mild flu-like symptoms 
(arthralgia and pyrexia) being the most common adverse 
events.26,45,46,49 Among the 4 phase III trials, osteonecrosis of 
the jaw (ONJ) was suspected in 6 of 3998 patients; however, 
Figure 4 Zoledronic acid prevents chemotherapy-associated bone loss in premenopausal women. Shown are percentage changes in lumbar spine, total hip, and femoral 
neck bone mineral density (BMD) from baseline to 6 and 12 months. Patients were randomly assigned to chemotherapy plus zoledronic acid (4 mg every 3 months) or 
placebo for 12 months. ap  0.001 (between group). P values were calculated using 2-sample t-tests for mean differences from baseline. Hershman DL, et al. J Clin Oncol. 2008; 
26(29):4739–4745.48 reprinted with permission. © 2008 American Society of Clinical Oncology.   All rights reserved.OncoTargets and Therapy 2009:2 101
Zoledronic acid in early breast cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
only 1 case (0.05%) has been confirmed by the ONJ 
Adjudication Committee.26,45,46,49 In the same 4 trials, only 
3 patients were suspected to have renal function impairment 
related to bisphosphonate treatment.26,45,46,49 In the adjuvant 
therapy setting, adverse events related to bisphosphonate 
therapy are mild and easily manageable, and the risk of 
rare adverse events can be further reduced with preventive 
measures and proper patient surveillance.51,52
Discussion
Historically, bisphosphonates have been used to treat 
patients with advanced breast cancer and bone metastases, 
and have been shown to reduce SREs in clinical trials.53 For 
example, in patients with bone metastases from breast cancer, 
bisphosphonates reduced the proportion of patients who 
experienced SREs compared with placebo in phase III trials 
of pamidronate (N = 754; p  0.001),54 ibandronate (N = 466; 
p = 0.052),55 and zoledronic acid (N = 228; p = 0.003).56 
However, the role of bisphosphonates may now expand 
to include protection of bone health in patients with early 
breast cancer receiving adjuvant endocrine therapy. Recent 
clinical trials have shown that bisphosphonates can prevent 
aromatase inhibitor-associated bone loss (AIBL) in postmeno-
pausal patients receiving adjuvant endocrine therapy.22,25,26,57 
Likewise, premenopausal patients with early breast cancer 
receiving adjuvant endocrine therapy can also benefit from 
the bone-protective effects of zoledronic acid.9
Recent evidence from clinical trials suggests that, in addi-
tion to its bone-preserving properties during adjuvant therapy, 
zoledronic acid’s antitumor properties may reduce disease 
recurrence when it is combined with adjuvant endocrine 
therapy. Although the mechanism of zoledronic acid-mediated 
inhibition of CTIBL depends on inhibition of osteoclast-
mediated bone resorption, the mechanisms underlying the 
significant improvements in DFS observed in premenopausal 
and postmenopausal patients with early breast cancer are 
likely to be multifactorial. In ABCSG-12, patients receiving 
endocrine therapy plus zoledronic acid experienced fewer dis-
ease events (disease recurrence or death) than those receiving 
endocrine therapy alone. In this setting, zoledronic acid not 
only reduced the number of patients with bone metastases, 
but also reduced distant recurrence, locoregional recurrence, 
Figure 5 Disease-free survival in premenopausal patients with early breast cancer receiving adjuvant endocrine therapy plus zoledronic acid. Kaplan-Meier plots of disease-free 
survival are shown for women with breast cancer who received adjuvant endocrine therapy with or without zoledronic acid (ZOL versus No ZOL). ZOL denotes anastrozole/
goserelin and tamoxifen/goserelin plus zoledronic acid; No ZOL denotes anastrozole/goserelin and tamoxifen/goserelin without zoledronic acid. Adapted with permission 
from Gnant M, Mlineritsch B, Schippinger w, et al. endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–691.49 Copyright © 
2009 Massachusetts Medical Society.   All rights reserved.OncoTargets and Therapy 2009:2 102
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and contralateral breast cancer.49 Reductions in locoregional 
and distant recurrences (including bone) were also observed 
in postmenopausal patients who received upfront zoledronic 
acid combined with letrozole in the ZO-FAST study.46 These 
data suggest that zoledronic acid may improve DFS by exert-
ing antitumor effects both within and outside of bone.
Interestingly, improved DFS with bisphosphonate 
treatment has been previously reported.58 The risk of bone 
metastases was reduced in patients with breast cancer who 
received oral clodronate for 2 years compared with no 
clodronate (N = 1069).59 However, no statistically significant 
differences in overall survival, bone metastasis-free survival, 
or nonskeletal metastasis-free survival were seen when a 
meta-analysis of this and subsequent clodronate trials in the 
adjuvant setting was conducted (N = 1653).60 Nonetheless, 
other phase III trials of bisphosphonates for early breast 
cancer are underway.
The possible mechanisms behind the antitumor effects 
of zoledronic acid may be provided in part by much of the 
preclinical study data demonstrating the antitumor proper-
ties of zoledronic acid including induction of tumor cell 
apoptosis, inhibition of tumor angiogenesis, immune cell 
activation, and decreased adhesion of tumor cells to bone 
(Figure 1).29,39,61–64 Although the antitumor effects observed 
for in vitro and in vivo preclinical studies are very clear, the 
question that remains is how a compound that preferentially 
binds to bone exerts such broad-reaching antitumor effects in 
the clinic. A hypothesis proposed in 1889 by Stephen Paget 
that the bone microenvironment influences tumor growth 
(“seed and soil” hypothesis) may offer a partial explanation 
for improved DFS in zoledronic acid-treated patients. In the 
Z-FAST, ZO-FAST, and E-ZO-FAST trials, and in the bone 
substudy of ABCSG-12 in the adjuvant therapy setting,9,25,26,57 
zoledronic acid (4 mg every 6 months) effectively prevented 
AIBL, possibly rendering the bone microenvironment a less 
favorable “soil” for tumor growth. This idea is borne out by 
4 phase I trials (N = 435) demonstrating that zoledronic acid-
treated breast cancer patients had reduced micrometastases 
in their bone marrow.65–68 For example, in 1 study (N = 45), 
zoledronic acid (4 mg monthly) significantly reduced the 
mean number of tumor cells in bone marrow at 24 months 
(p = 0.0026), with reductions in 71% of patients.66 According 
to the seed-and-soil hypothesis, zoledronic acid in bone may 
thereby limit the future seeding of tumor cells to more distant 
sites. Because there appears to be a significant correlation 
between tumor cells in bone marrow and the risk of distant 
relapse,69 the idea that reducing or eliminating bone marrow 
micrometastases will prevent distant disease recurrence 
seems plausible. However, further studies will be needed 
to define the precise antitumor mechanisms involved in the 
adjuvant therapy setting.
In summary, zoledronic acid has demonstrated consid-
erable efficacy for preventing CTIBL in patients with early 
breast cancer. Additional evidence from some of these clini-
cal trials indicates that adding zoledronic acid to adjuvant 
endocrine therapy can significantly improve DFS beyond 
what is achieved with endocrine therapy alone. Because of 
the favorable side-effect profile of zoledronic acid in the 
adjuvant setting and the significant bone health and survival 
benefits achieved, it is likely that zoledronic acid may become 
part of standard adjuvant therapy for early breast cancer. 
Although this review has focused on results from trials of 
zoledronic acid in patients with early breast cancer, several 
ongoing phase III clinical studies are examining the efficacy 
of zoledronic acid for preventing bone metastases in breast, 
lung, prostate, and other cancers (eg, AZURE, SUCCESS, 
NATAN, SWOG 0307, NSABP B-34, AZAC, study 2419, 
ZEUS, STAMPEDE, and RADAR). Results from these 
ongoing studies will likely continue to shape the role of 
zoledronic acid in the early cancer settings.
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